News Release

share on google plus
Text size
view with small font size
view with medium font size
view with large font size

October 30, 2014

Completion of Construction for Drug Product Manufacturing Facility in the Takasaki Plant

Tokyo, Japan, October 30, 2014 --- Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151, President and CEO: Nobuo Hanai, "Kyowa Hakko Kirin") has completed the construction of the HA5 Plant in the Takasaki Plant (Takasaki city, Gunma, Plant Manager: Koichi Nishimura) in October 2014.

As a part of its production site reorganization, the manufacture of some products currently made at the Fuji Plant (Suntou-gun, Shizuoka) will be transferred to the new HA5 Plant. In addition to these production transfers, the new HA5 Plant is also scheduled to manufacture those drug products currently produced at the Takasaki Plant's existing drug manufacturing facility, as well as new products that the company will hereafter develop. The HA5 Plant is designed for efficient manufacture of multiple products, with a focus on biopharmaceutical injection drugs. It will be operated in accordance with the Good Manufacturing Practices (GMP) for European, U.S., and Japanese drug products, and will thus be able to supply products globally. The HA5 Plant is also a seismic isolated building and has an emergency power supply to ensure continued operation in the event of a natural disaster. It will start operations in 2016, and begin commercial production in 2017.

Kyowa Hakko Kirin will continue to strengthen its production system to ensure the stable supply of high-quality pharmaceutical products to patients.


<External Appearance of HA5 Plant>



<New plant overview>

Plant name: HA5 Plant
Scale: Steel construction, four stories, total floor area of approx. 4106 m2
Investment: Approx. 4.6 billion yen
Purpose: Manufacture of injection drugs
Schedule: Start of operations: 2016
Launch of commercial production: 2017
Characteristics: (1) Able to manufacture multiple products, with a focus on biopharmaceutical drugs in freeze-dried and liquid form.
(2) Complies with GMP in Japan, the US, and the EU.
(3) Base isolated system and emergency power supply system.


Contact:

Kyowa Hakko Kirin
Media Contact:
+81-3-3282-1903
or
Investors:
+81-3-3282-0009



To Page Top